May 2, 2013
Astellas Pharma announced on April 30 that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for its oral androgen receptor signaling inhibitor Xtandi (enzalutamide) capsules for the treatment of adult men...read more